BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 22608401)

  • 1. Multimodality therapy offers a chance for cure in patients with pancreatic adenocarcinoma deemed unresectable at first operative exploration.
    Truty MJ; Thomas RM; Katz MH; Vauthey JN; Crane C; Varadhachary GR; Wolff RA; Abbruzzese JL; Lee JE; Fleming JB
    J Am Coll Surg; 2012 Jul; 215(1):41-51; discussion 51-2. PubMed ID: 22608401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a "true" R0 resection?
    Konstantinidis IT; Warshaw AL; Allen JN; Blaszkowsky LS; Castillo CF; Deshpande V; Hong TS; Kwak EL; Lauwers GY; Ryan DP; Wargo JA; Lillemoe KD; Ferrone CR
    Ann Surg; 2013 Apr; 257(4):731-6. PubMed ID: 22968073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival.
    Massucco P; Capussotti L; Magnino A; Sperti E; Gatti M; Muratore A; Sgotto E; Gabriele P; Aglietta M
    Ann Surg Oncol; 2006 Sep; 13(9):1201-8. PubMed ID: 16955382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-resolution pancreatic computed tomography for assessing pancreatic ductal adenocarcinoma resectability: a multicenter prospective study.
    Lee DH; Ha HI; Jang JY; Lee JW; Choi JY; Bang S; Lee CH; Kim WB; Lee SS; Kim SC; Kang BK; Lee JM
    Eur Radiol; 2023 Sep; 33(9):5965-5975. PubMed ID: 36988715
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resectability After First-Line FOLFIRINOX in Initially Unresectable Locally Advanced Pancreatic Cancer: A Single-Center Experience.
    Nitsche U; Wenzel P; Siveke JT; Braren R; Holzapfel K; Schlitter AM; Stöß C; Kong B; Esposito I; Erkan M; Michalski CW; Friess H; Kleeff J
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S1212-20. PubMed ID: 26350368
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Surgery after FOLFIRINOX treatment for locally advanced and borderline resectable pancreatic cancer: increase in tumour attenuation on CT correlates with R0 resection.
    Marchegiani G; Todaro V; Boninsegna E; Negrelli R; Sureka B; Bonamini D; Salvia R; Manfredi R; Pozzi Mucelli R; Bassi C
    Eur Radiol; 2018 Oct; 28(10):4265-4273. PubMed ID: 29679211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pancreatic carcinoma deemed unresectable at exploration may be resected for cure: an institutional experience.
    Chao C; Hoffman JP; Ross EA; Torosian MH; Eisenberg BL
    Am Surg; 2000 Apr; 66(4):378-85; discussion 386. PubMed ID: 10776876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
    Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
    Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pancreas-protocol imaging at a high-volume center leads to improved preoperative staging of pancreatic ductal adenocarcinoma.
    Walters DM; Lapar DJ; de Lange EE; Sarti M; Stokes JB; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Oct; 18(10):2764-71. PubMed ID: 21484522
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Second-look operation for unresectable pancreatic ductal adenocarcinoma at a high-volume center.
    Michalski CW; Kleeff J; Bachmann J; Alkhatib J; Erkan M; Esposito I; Hinz U; Friess H; Büchler MW
    Ann Surg Oncol; 2008 Jan; 15(1):186-92. PubMed ID: 17943388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgical management of pancreatic neoplasms: what's new?
    Karachristos A; Esnaola NF
    Curr Gastroenterol Rep; 2014 Aug; 16(8):397. PubMed ID: 25064316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraoperative Radiation Therapy (IORT) for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (BR/LA PDAC) in the Era of Modern Neoadjuvant Treatment: Short-Term and Long-Term Outcomes.
    Harrison JM; Wo JY; Ferrone CR; Horick NK; Keane FK; Qadan M; Lillemoe KD; Hong TS; Clark JW; Blaszkowsky LS; Allen JN; Castillo CF
    Ann Surg Oncol; 2020 May; 27(5):1400-1406. PubMed ID: 31758284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.
    Barugola G; Partelli S; Crippa S; Capelli P; D'Onofrio M; Pederzoli P; Falconi M
    Am J Surg; 2012 Feb; 203(2):132-9. PubMed ID: 21824596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Surgical resection after radiochemotherapy in patients with unresectable adenocarcinoma of the pancreas.
    Sa Cunha A; Rault A; Laurent C; Adhoute X; Vendrely V; Béllannée G; Brunet R; Collet D; Masson B
    J Am Coll Surg; 2005 Sep; 201(3):359-65. PubMed ID: 16125068
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma.
    Hu Q; Wang D; Chen Y; Li X; Cao P; Cao D
    Radiat Oncol; 2019 Jul; 14(1):120. PubMed ID: 31291998
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative capecitabine and concurrent radiation for borderline resectable pancreatic cancer.
    Stokes JB; Nolan NJ; Stelow EB; Walters DM; Weiss GR; de Lange EE; Rich TA; Adams RB; Bauer TW
    Ann Surg Oncol; 2011 Mar; 18(3):619-27. PubMed ID: 21213060
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CT-determined resectability of borderline resectable and unresectable pancreatic adenocarcinoma following FOLFIRINOX therapy.
    Jang JK; Byun JH; Kang JH; Son JH; Kim JH; Lee SS; Kim HJ; Yoo C; Kim KP; Hong SM; Seo DW; Kim SC; Lee MG
    Eur Radiol; 2021 Feb; 31(2):813-823. PubMed ID: 32845389
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Staging of pancreatic cancer: resectable, borderline resectable, and unresectable disease.
    Soloff EV; Zaheer A; Meier J; Zins M; Tamm EP
    Abdom Radiol (NY); 2018 Feb; 43(2):301-313. PubMed ID: 29198002
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics of Patients Experiencing Pathologic Complete Response Following Neoadjuvant Therapy for Borderline Resectable/Locally Advanced Pancreatic Adenocarcinoma.
    Hashemi-Sadraei N; Gbolahan OB; Salfity H; O'Neil B; House MG; Shahda S
    Am J Clin Oncol; 2018 Oct; 41(10):982-985. PubMed ID: 28968257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neoadjuvant therapy for localized pancreatic ductal adenocarcinoma.
    Brown ZJ; Shannon AH; Cloyd JM
    Minerva Surg; 2024 Jun; 79(3):315-325. PubMed ID: 38385797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.